Developer docs
API playgroundTry for free, no card

Search company profiles

Skye Bioscience

Full company profile

uuid000041w

Namestring
Skye Bioscience
Legal namestring
Skye Bioscience, Inc.
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Skye Bioscience, Inc. is a clinical-stage biotechnology company developing therapeutics targeting the endocannabinoid system, with a primary focus on obesity and metabolic diseases. The company's lead asset is nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody that uses allosteric modulation and is designed with very limited CNS penetration to avoid the neuropsychiatric adverse events associated with earlier small-molecule CB1 inhibitors. The technology is supported by dual drug-delivery collaborations — with Halozyme (ENHANZE for subcutaneous high-volume delivery) and Arecor (Arestat for high-concentration auto-injector formulation) — intended to enable weekly or monthly subcutaneous dosing at the higher doses required for obesity treatment.

The company operates a sales-led go-to-market posture oriented toward endocrinologists, obesity medicine specialists, and key opinion leaders via medical conferences (ObesityWeek, ADA, ECO, GLP-1 Summit), peer-reviewed publications, and investor communications. As a clinical-stage company, Skye has no commercial products and no product revenue; its economics are driven entirely by R&D expenditure, with a 2025 net loss of $55.9 million against a cash position of $17.1 million as of March 31, 2026. The CBeyond Phase 2a trial in obesity reported positive combination data (nimacimab plus semaglutide achieving 22.3% mean weight loss at 52 weeks with limited rebound) but the 200mg monotherapy arm failed its primary endpoint due to under-exposure relative to preclinical predictions, prompting a higher-dose expansion study initiated in April 2026.

The business model is a standard clinical-stage biotech equity-financing model: capital is raised through public equity (NASDAQ: SKYE) and private placements, with future revenue contingent on regulatory approval and prescription pharmaceutical distribution. The company faces material near-term risks including a Nasdaq minimum bid price deficiency notice (compliance deadline September 14, 2026), multiple securities fraud class action lawsuits related to alleged misstatements about nimacimab's efficacy, an employee stock option repricing to $0.6150 per share, and a cash runway that requires additional financing within approximately two quarters at the current burn rate.

Short descriptiontext

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody for obesity and metabolic diseases, with no commercial products or revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
obesity therapeutics, CB1 receptor inhibition, monoclonal antibody drugs, metabolic disease treatment, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Obesity and Metabolic Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Skye Bioscience is a clinical-stage biotechnology company with no current commercial products or revenue. The company is developing nimacimab, a peripheral CB1-inhibiting antibody for obesity and metabolic diseases. If successfully developed and approved by regulatory authorities, the company would generate revenue through the sale of prescription pharmaceutical products.

skyebioscience.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody for the treatment of obesity and metabolic diseases. The company is advancing the drug through Phase 2 clinical trials (CBeyond), both as monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, with the intent of obtaining regulatory approval for prescription pharmaceutical sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 22.3% mean weight loss at 52 weeks with nimacimab + semaglutide combination therapy
+5 more records
Product overview1 text field

Skye Bioscience is a clinical-stage biotechnology company developing next-generation drugs to treat obesity and other metabolic diseases. The company's primary product is nimacimab, a peripherally-restricted CB1-inhibiting monoclonal antibody in Phase 2 clinical development for obesity. Nimacimab is being evaluated both as monotherapy and in combination with GLP-1 receptor agonists (semaglutide/Wegovy) in the CBeyond Phase 2a trial. The company focuses on first-in-class molecules that modulate G-protein coupled receptors, with an emphasis on addressing unmet needs in the obesity market where current GLP-1 therapies have limitations related to gastrointestinal side effects, muscle loss, and weight rebound after treatment discontinuation.

Product and service1 record
1Nimacimab
CategoryObesity and Metabolic Disease Therapeutics
Description

Nimacimab is a potentially first-in-class peripheral CB1-inhibiting monoclonal antibody being developed for obesity and metabolic diseases. It targets CB1 receptors in peripheral tissues including adipose, liver, and muscle, with very limited accumulation in the CNS, offering weight loss through increased energy expenditure, improved leptin sensitivity, and appetite modulation with better gastrointestinal tolerability and muscle preservation compared to GLP-1 therapeutics.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Non-exclusive global collaboration and license agreement to develop a subcutaneous formulation of nimacimab for obesity treatment using Halozyme's ENHANZE drug delivery technology. Skye will make milestone payments tied to development and commercialization achievements, while Halozyme will receive mid-single digit royalties on net sales for at least 10 years. Skye plans to initiate a Phase 2b clinical trial for nimacimab with ENHANZE in mid-2026, which will also assess combination with a GLP-1R agonist.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Engagement with Lilly Catalyze360 for Phase 2b trial design advisory services. The partnership provides strategic consulting for clinical trial design and development strategy for nimacimab.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnership focused on achieving higher-concentration nimacimab formulations using Arecor's Arestat technology to enable simple, low-viscosity subcutaneous auto-injector delivery. This technology complements the ENHANZE partnership to address high-dose delivery challenges for obesity treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity. Highly comparable to Skye as a similarly-sized, single-asset, pre-revenue obesity company navigating Phase 2 development with strategic optionality around partnership or acquisition.

TypeBroad incumbent
Description

Large-cap biotech developing MariTide (AMG 133), an obesity candidate in Phase 2/3. Directly competes with nimacimab in the cardiometabolic/obesity space and represents the type of strategic acquirer Skye would likely need for commercial success.

TypeBroad incumbent
Description

Market leader in incretin-based obesity therapeutics (tirzepatide/Zepbound, retatrutide). The dominant competitor any CB1-inhibitor must position against and a potential strategic partner interested in complementary mechanisms to its GLP-1 franchise.

TypeBroad incumbent
Description

Developer of semaglutide (Wegovy/Ozempic), the incumbent GLP-1 agonist and Skye's combination partner in the CBeyond trial. Sets the efficacy benchmark nimacimab must beat or complement to gain commercial relevance.

TypeDirect peer
Description

Clinical-stage peptide company developing amylin analogs (e.g., BI 456906 with Boehringer Ingelheim) and other metabolic-disease candidates. Comparable as a small-cap, single-mechanism challenger pursuing differentiated obesity mechanisms against the GLP-1 incumbents.

TypeDirect peer
Description

Clinical-stage company developing oral GLP-1 agonists (GSBR-1290) and other metabolic candidates. Similar profile to Skye: small-cap, single-platform, Phase 2 obesity focus with mechanism differentiation (oral vs. injectable).

TypeBroad incumbent
Description

Major pharma developing oral GLP-1 candidates (danuglipron) for obesity and metabolic disease. A potential strategic partner for Skye and a competitor for share-of-voice with endocrinologists and obesity specialists.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for hematologic and metabolic disorders. Comparable as a small-cap, single-mechanism biotech with clinical-stage assets in metabolic disease areas.

TypeEmerging player
Description

Emerging clinical-stage company developing ARD-101 for Prader-Willi syndrome and other metabolic indications. Comparable as a small, single-asset biotech pursuing differentiated metabolic mechanisms with similar regulatory and capital-raising challenges as Skye.

TypeEmerging player
Description

Clinical-stage company developing miniature, long-acting implants for chronic conditions including obesity (NPM-115). Comparable as a small-cap, single-asset, pre-revenue company pursuing differentiated obesity mechanisms in a GLP-1-dominated market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Skye Bioscience

Obesity and Metabolic Disease Therapeuticsskyebioscience.com

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody for obesity and metabolic diseases, with no commercial products or revenue.

What Skye Bioscience does

Skye Bioscience, Inc. is a clinical-stage biotechnology company developing therapeutics targeting the endocannabinoid system, with a primary focus on obesity and metabolic diseases. The company's lead asset is nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody that uses allosteric modulation and is designed with very limited CNS penetration to avoid the neuropsychiatric adverse events associated with earlier small-molecule CB1 inhibitors. The technology is supported by dual drug-delivery collaborations — with Halozyme (ENHANZE for subcutaneous high-volume delivery) and Arecor (Arestat for high-concentration auto-injector formulation) — intended to enable weekly or monthly subcutaneous dosing at the higher doses required for obesity treatment.

The company operates a sales-led go-to-market posture oriented toward endocrinologists, obesity medicine specialists, and key opinion leaders via medical conferences (ObesityWeek, ADA, ECO, GLP-1 Summit), peer-reviewed publications, and investor communications. As a clinical-stage company, Skye has no commercial products and no product revenue; its economics are driven entirely by R&D expenditure, with a 2025 net loss of $55.9 million against a cash position of $17.1 million as of March 31, 2026. The CBeyond Phase 2a trial in obesity reported positive combination data (nimacimab plus semaglutide achieving 22.3% mean weight loss at 52 weeks with limited rebound) but the 200mg monotherapy arm failed its primary endpoint due to under-exposure relative to preclinical predictions, prompting a higher-dose expansion study initiated in April 2026.

The business model is a standard clinical-stage biotech equity-financing model: capital is raised through public equity (NASDAQ: SKYE) and private placements, with future revenue contingent on regulatory approval and prescription pharmaceutical distribution. The company faces material near-term risks including a Nasdaq minimum bid price deficiency notice (compliance deadline September 14, 2026), multiple securities fraud class action lawsuits related to alleged misstatements about nimacimab's efficacy, an employee stock option repricing to $0.6150 per share, and a cash runway that requires additional financing within approximately two quarters at the current burn rate.

Skye Bioscience firmographics

Firmographics
Name
Skye Bioscience
Legal name
Skye Bioscience, Inc.
Website
https://skyebioscience.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody for obesity and metabolic diseases, with no commercial products or revenue.
Ownership category
akta.pro rank

Skye Bioscience industry classification

Industry
Product category
Obesity and Metabolic Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Obesity therapeutics
  • CB1 receptor inhibition
  • Monoclonal antibody drugs
  • Metabolic disease treatment
  • Clinical-stage biotechnology

Where Skye Bioscience is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Skye Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Drug Sales: Skye Bioscience is a clinical-stage biotechnology company with no current commercial products or revenue. The company is developing nimacimab, a peripheral CB1-inhibiting antibody for obesity and metabolic diseases. If successfully developed and approved by regulatory authorities, the company would generate revenue through the sale of prescription pharmaceutical products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Skye Bioscience product offering

Product offering

Core offering

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody for the treatment of obesity and metabolic diseases. The company is advancing the drug through Phase 2 clinical trials (CBeyond), both as monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, with the intent of obtaining regulatory approval for prescription pharmaceutical sales.

Product overview

Skye Bioscience is a clinical-stage biotechnology company developing next-generation drugs to treat obesity and other metabolic diseases. The company's primary product is nimacimab, a peripherally-restricted CB1-inhibiting monoclonal antibody in Phase 2 clinical development for obesity. Nimacimab is being evaluated both as monotherapy and in combination with GLP-1 receptor agonists (semaglutide/Wegovy) in the CBeyond Phase 2a trial. The company focuses on first-in-class molecules that modulate G-protein coupled receptors, with an emphasis on addressing unmet needs in the obesity market where current GLP-1 therapies have limitations related to gastrointestinal side effects, muscle loss, and weight rebound after treatment discontinuation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nimacimab Nimacimab is a potentially first-in-class peripheral CB1-inhibiting monoclonal antibody being developed for obesity and metabolic diseases. It targets CB1 receptors in peripheral tissues including adipose, liver, and muscle, with very limited accumulation in the CNS, offering weight loss through increased energy expenditure, improved leptin sensitivity, and appetite modulation with better gastrointestinal tolerability and muscle preservation compared to GLP-1 therapeutics.

Quantifiable outcome

  • 22.3% mean weight loss at 52 weeks with nimacimab + semaglutide combination therapy
  • +5 more outcomes

Companies that use Skye Bioscience

Customer profile

Segments3 records

Ideal customer profiles2 records

Skye Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Skye Bioscience partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Halozyme TherapeuticscoreTechnology or Integration · 1 December 2025Non-exclusive global collaboration and license agreement to develop a subcutaneous formulation of nimacimab for obesity treatment using Halozyme's ENHANZE drug delivery technology. Skye will make milestone payments tied to development and commercialization achievements, while Halozyme will receive mid-single digit royalties on net sales for at least 10 years. Skye plans to initiate a Phase 2b clinical trial for nimacimab with ENHANZE in mid-2026, which will also assess combination with a GLP-1R agonist.
  • Lilly Catalyze360supportingStrategic or Co-development Partner · 1 December 2025Engagement with Lilly Catalyze360 for Phase 2b trial design advisory services. The partnership provides strategic consulting for clinical trial design and development strategy for nimacimab.
  • Arecor TherapeuticssupportingTechnology or IntegrationPartnership focused on achieving higher-concentration nimacimab formulations using Arecor's Arestat technology to enable simple, low-viscosity subcutaneous auto-injector delivery. This technology complements the ENHANZE partnership to address high-dose delivery challenges for obesity treatment.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Skye Bioscience competitors and assessment

Company assessment

Direct peers

  • Altimmune: Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity. Highly comparable to Skye as a similarly-sized, single-asset, pre-revenue obesity company navigating Phase 2 development with strategic optionality around partnership or acquisition.
  • Zealand Pharma: Clinical-stage peptide company developing amylin analogs (e.g., BI 456906 with Boehringer Ingelheim) and other metabolic-disease candidates. Comparable as a small-cap, single-mechanism challenger pursuing differentiated obesity mechanisms against the GLP-1 incumbents.
  • Structure Therapeutics: Clinical-stage company developing oral GLP-1 agonists (GSBR-1290) and other metabolic candidates. Similar profile to Skye: small-cap, single-platform, Phase 2 obesity focus with mechanism differentiation (oral vs. injectable).
  • Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for hematologic and metabolic disorders. Comparable as a small-cap, single-mechanism biotech with clinical-stage assets in metabolic disease areas.

Broad incumbents

  • Amgen: Large-cap biotech developing MariTide (AMG 133), an obesity candidate in Phase 2/3. Directly competes with nimacimab in the cardiometabolic/obesity space and represents the type of strategic acquirer Skye would likely need for commercial success.
  • Eli Lilly: Market leader in incretin-based obesity therapeutics (tirzepatide/Zepbound, retatrutide). The dominant competitor any CB1-inhibitor must position against and a potential strategic partner interested in complementary mechanisms to its GLP-1 franchise.
  • Novo Nordisk: Developer of semaglutide (Wegovy/Ozempic), the incumbent GLP-1 agonist and Skye's combination partner in the CBeyond trial. Sets the efficacy benchmark nimacimab must beat or complement to gain commercial relevance.
  • Pfizer: Major pharma developing oral GLP-1 candidates (danuglipron) for obesity and metabolic disease. A potential strategic partner for Skye and a competitor for share-of-voice with endocrinologists and obesity specialists.

Emerging players

  • Aardvark Therapeutics: Emerging clinical-stage company developing ARD-101 for Prader-Willi syndrome and other metabolic indications. Comparable as a small, single-asset biotech pursuing differentiated metabolic mechanisms with similar regulatory and capital-raising challenges as Skye.
  • Vivani Medical: Clinical-stage company developing miniature, long-acting implants for chronic conditions including obesity (NPM-115). Comparable as a small-cap, single-asset, pre-revenue company pursuing differentiated obesity mechanisms in a GLP-1-dominated market.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Skye Bioscience social profiles

Digital presence

Skye Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Skye Bioscience leadership team

Management profile

Number of profiles

Profiles10 records

Skye Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Skye Bioscience funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Skye Bioscience M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skye Bioscience

What does Skye Bioscience do?

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a first-in-class peripheral CB1-inhibiting monoclonal antibody for the treatment of obesity and metabolic diseases. The company is advancing the drug through Phase 2 clinical trials (CBeyond), both as monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, with the intent of obtaining regulatory approval for prescription pharmaceutical sales.

Is Skye Bioscience a public or private company?

Skye Bioscience is a public company. It is classified as public and is currently operating.

When was Skye Bioscience founded?

Skye Bioscience was founded in 2011. It employs 11 to 50 people.

Where is Skye Bioscience based?

Skye Bioscience is headquartered in San Diego, United States, in the North America region.

How does Skye Bioscience make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Skye Bioscience's main competitors?

Direct peers on record are Altimmune, Zealand Pharma, Structure Therapeutics and Keros Therapeutics. Broad incumbents are Amgen, Eli Lilly, Novo Nordisk and Pfizer. Emerging players are Aardvark Therapeutics and Vivani Medical.

Does Skye Bioscience have an API?

No public API is recorded for Skye Bioscience.

What industry is Skye Bioscience in?

Skye Bioscience's product category is Obesity and Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comStock Market News - Investing.com IndiaAndrew J. Schwab, a director and 10% owner of Skye Bioscience, sold approximately $239,555 of common stock on September 22-23, 2026. The company also received a Nasdaq notice for failing to meet the $2.5 million minimum stockholders' equity, reporting negative $497,307 equity.European BiotechnologyRedx raises $36M to fund Phase 2 Crohn’s disease trialRedx raised $36M in a Series A round, led by Abingworth, to fund its Phase 2 trial of gut-restricted ROCK inhibitor RXC008 for fibrostenotic Crohn's disease. The financing includes a $68M private placement, extending the combined company's cash runway to 2029. Redx aims to report Phase 2 topline data in the second half of 2028.BenzingaSkye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move - Skye Bioscience (NASDSkye Bioscience shares rose 6.20% to $2.14 in after-hours trading Tuesday, following a 7.14% drop to $2.02 in regular session trading. The biotechnology company entered a securities purchase agreement with Redmile Biopharma Investments III, L.P. on Aug. 21, obligating the investor to buy up to $22 million of equity over three years, with monthly purchases capped at $2 million.TipranksUpcoming Stock Splits This Week (August 24 to August 28) – Stay InvestedA series of companies, including IES Holdings, Black Rifle Coffee, and Skye Bioscience, are implementing stock splits or reverse splits effective between August 24 and August 28. These corporate actions range from traditional two-for-one splits aimed at improving liquidity to multiple reverse splits designed to meet Nasdaq and NYSE minimum bid price requirements for continued listing compliance.Investing.comSkye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.comAndrew Schwab, a director and 10% owner of Skye Bioscience, sold common stock valued at $140,313 between August 18 and August 20, 2026. The sales occurred while the company faces Nasdaq non-compliance notices regarding its negative stockholders' equity and is advancing clinical trials for nimacimab.Investing.comSkye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.comAndrew Schwab, a director and major shareholder of Skye Bioscience, sold approximately $140,313 worth of the company's stock between August 18 and 20, 2026. This transaction occurs as Skye Bioscience faces Nasdaq non-compliance notices regarding its negative stockholders' equity while simultaneously advancing clinical trials for nimacimab with the approval of a second study cohort.Markets DailySkye Bioscience (NASDAQ:SKYE) Major Shareholder Sells $23,849.00 in StockMajor shareholder 5Am Partners Vii, Llc sold approximately $23,849 worth of Skye Bioscience stock on August 19th, reducing its position by over 55%. The company is scheduled to execute an 1-8 reverse stock split on August 24th. Additionally, institutional investors have adjusted their stakes in the biotechnology firm during recent quarters.Quiver QuantitativeInsider Sale: Director at $SKYE Sells 46 Shares | SKYE Stock NewsAndrew J. Schwab, a director at SKYE, sold 46 shares on August 20, 2026, reducing his stake in the company. This transaction is part of a broader trend where SKYE insiders executed 18 sales against zero purchases over the past six months. Additionally, several major institutional investors, including Schonfeld Strategic Advisors and Millennium Management, significantly reduced their positions in SKYE during recent quarters.Markets DailySkye Bioscience Stock Set to Reverse Split on Monday, August 24th (NASDAQ:SKYE)Skye Bioscience, Inc. announced a 1-for-8 reverse stock split scheduled to take effect before market open on Monday, August 24th. The company's share count will be adjusted following the closing bell on Sunday, August 23rd. This move comes as Skye Bioscience continues to operate with a low market capitalization and negative earnings per share.